 Regeneron Pharmaceuticals Inc. and Sanofi SA are spending $67.5 million on a novel bet they hope will help them outflank Amgen Inc. in the race to get a new class of cholesterol drugs to the market.. The companies are paying the money to acquire a special voucher held by BioMarin Pharmaceuticals Inc. in a bid to hasten regulatory review of their drug alirocumab, one of an emerging group of medicines that lower cholesterol by targeting a gene known as PCSK9.